An excerpt of European Society for Organ Transplantation consensus statement on biomarkers in liver transplantation （2023）

Corresponding author: ZHANG Yamin， 13802122219@163.com （ORICD： 0000-0001-7886-2901）
Received Date: 2023-11-30
Accepted Date: 2023-12-04
Published Date: 2024-02-19

Abstract

Abstract

In August 2023， the European Society for Organ Transplantation （ESOT） published the ESOT Consensus Statement on Biomarkers in Liver Transplantation online. The consensus statement focuses on biomarkers in liver transplantation， clinical applicability， and future needs and explores the role of new biomarkers in predicting liver transplantation outcomes by reviewing the literature on primary disease recurrence， development of chronic kidney disease （CKD）， and safe weaning of immunosuppression. This consensus statement conducts studies from the four aspects of recurrent liver disease after liver transplantation， recurrent hepatocellular carcinoma， weaning of immunosuppression， and CKD progression， emphasizes the importance of biomarkers in predicting or detecting disease recurrence， and proposes that large-scale prospective studies are still needed to improve the quality of evidence. The author’s team gives an excerpt of the consensus statement and systematically introduces the four aspects of the consensus statement and related discussions and conclusions， in order to provide more evidence-based medical evidence for identifying and exploring new biomarkers for liver transplantation.
- Liver Transplantation,
- Biomarkers,
- Consensus,
- Europe

FullText(HTML)

References(1)

References

[1]	BERENGUER M, de MARTIN E, HESSHEIMER AJ, et al. European Society for Organ Transplantation consensus statement on biomarkers in liver transplantation[J]. Transpl Int, 2023, 36: 11358. DOI: 10.3389/ti.2023.11358.

Relative Articles

[1]	Yanbin NI, Jiye ZHU. An excerpt of EASL clinical practice guidelines on liver transplantation （2024 edition）[J]. Journal of Clinical Hepatology, 2025, 41(2): 240-246. doi: 10.12449/JCH250208
[2]	Wenjing NI, Nan GENG, Xue BAI, Jie LI. An excerpt of EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease in 2024[J]. Journal of Clinical Hepatology, 2024, 40(8): 1567-1574. doi: 10.12449/JCH240810
[3]	Danqin SUN, Jiaqi SHEN, Minghua ZHENG. An excerpt of an international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease （2023）[J]. Journal of Clinical Hepatology, 2024, 40(1): 42-45. doi: 10.12449/JCH240108
[4]	Jiaofeng HUANG, Youbing LI, Yinlian WU, Ruimin LAI, Naling KANG, Ying ZHANG, Jiaji JIANG. An excerpt of EASL expert consensus on systemic therapy for hepatocellular carcinoma(2021)[J]. Journal of Clinical Hepatology, 2022, 38(2): 320-321. doi: 10.3969/j.issn.1001-5256.2022.02.013
[5]	Zheng KeXin, Yang Ling, Qi XingShun. An excerpt of care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID expert consensus(2020)[J]. Journal of Clinical Hepatology, 2020, 36(5): 989-990. doi: 10.3969/j.issn.1001-5256.2020.05.007
[6]	He YangLan, Wang YaDong, Qi XingShun. An excerpt of Perioperative hemostatic management in the cirrhotic patient: A position paper on behalf of the Liver Intensive Care Group of Europe (LICAGE) (2019)[J]. Journal of Clinical Hepatology, 2019, 35(10): 2192-2193. doi: 10.3969/j.issn.1001-5256.2019.10.012
[7]	Zhang DaLi, Liu HongLing. An excerpt of International Liver Transplant Society consensus statement on hepatitis C management in liver transplant candidates (2017)[J]. Journal of Clinical Hepatology, 2017, 33(9): 1658-1662. doi: 10.3969/j.issn.1001-5256.2017.09.007
[8]	Zheng SuLi, Zhang TaiPing. An excerpt of laparoscopic surgery for pancreatic neoplasms: the European Association for Endoscopic Surgery clinical consensus conference（2017）[J]. Journal of Clinical Hepatology, 2017, 33(5): 816-819. doi: 10.3969/j.issn.1001-5256.2017.05.004
[9]	Chen Lei, Chen LuZeng. An excerpt of EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (short version)[J]. Journal of Clinical Hepatology, 2017, 33(10): 1910-1915. doi: 10.3969/j.issn.1001-5256.2017.10.012
[10]	Yang Min, Zhang ShengGuo, Lu MingQin. EASL clinical practical guidelines on the management of acute(fulminant) liver failure(2017)[J]. Journal of Clinical Hepatology, 2017, 33(10): 1883-1887. doi: 10.3969/j.issn.1001-5256.2017.10.007
[11]	Shen ShanShan, Dai MingJia, Yan XueBing. Interpretation and analysis of EASL recommendations on treatment of hepatitis C 2016[J]. Journal of Clinical Hepatology, 2016, 32(12): 2258-2262. doi: 10.3969/j.issn.1001-5256.2016.12.006
[13]	Chang BinXia, Li BaoSen, Zou ZhengSheng. An excerpt of EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease(2016)[J]. Journal of Clinical Hepatology, 2016, 32(8): 1450-1454. doi: 10.3969/j.issn.1001-5256.2016.08.003
[14]	Chen JiaJia, Li WenGang. An excerpt of (2016) cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)[J]. Journal of Clinical Hepatology, 2016, 32(10): 1847-1850. doi: 10.3969/j.issn.1001-5256.2016.10.004
[15]	Shi YingHong, Tian MengXin, Fan Jia. Recommendations for EASL clinical practice guidelines: liver transplantation（2015）[J]. Journal of Clinical Hepatology, 2016, 32(3): 429-431. doi: 10.3969/j.issn.1001-5256.2016.03.005
[16]	Dai MingJia, Yan XueBing. A comparative analysis of 2014 and 2015 EASL guidelines for anti-HCV therapy[J]. Journal of Clinical Hepatology, 2015, 31(10): 1595-1598. doi: 10.3969/j.issn.1001-5256.2015.10.008
[17]	Rao HuiYing, Wei Lai. EASL recommendations on treatment of hepatitis C 2015[J]. Journal of Clinical Hepatology, 2015, 31(7): 1008-1017. doi: 10.3969/j.issn.1001-5256.2015.07.004
[18]	Wang XiaoXi, Qi XingShun, Guo XiaoZhong. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT) in 2015[J]. Journal of Clinical Hepatology, 2015, 31(5): 659-664. doi: 10.3969/j.issn.1001-5256.2015.05.005
[19]	Zhu Peng, Chen Qing, Wang Li, Wang YuMing. Recommendations of EASL clinical practice guidelines: management of hepatitis C virus infection[J]. Journal of Clinical Hepatology, 2014, 30(2): 109-112. doi: 10.3969/j.issn.1001-5256.2014.02.003
[20]	Cai JunJun, Han Tao. Bacterial infections in cirrhosis: a summary of position statement based on the EASL Special Conference 2013[J]. Journal of Clinical Hepatology, 2014, 30(7): 588-591. doi: 10.3969/j.issn.1001-5256.2014.07.003

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(7)

Get Citation

PDF

XML

Article Metrics

Article views (445) PDF downloads(80)

An excerpt of European Society for Organ Transplantation consensus statement on biomarkers in liver transplantation （2023）

DOI: 10.12449/JCH240206

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

An excerpt of European Society for Organ Transplantation consensus statement on biomarkers in liver transplantation （2023）

DOI: 10.12449/JCH240206

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content